Bo Wang, He-Shui Wu, Guo-Bin Wang, Kai-Xiong Tao
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
J Invest Surg. 2013 Jun;26(3):154-7. doi: 10.3109/08941939.2012.691604. Epub 2013 Apr 25.
This study is aimed to evaluate the feasibility of laparoscopic splenectomy (LS) for massive splenomegaly in patients with hypersplenism secondary to portal hypertension and liver cirrhosis.
A retrospective study of adult patients was conducted for splenectomy occurring from January 2006 to December 2010. We have performed the surgical procedures of splenectomy in 80 patients who were suffering from splenomegaly or hypersplenism secondary to portal hypertension and liver cirrhosis, among whom 40 patients underwent LS and another 40 patients received open surgery (OS).
Among the patients who had undergone LS, 2 patients were converted to OS and the other 38 patients underwent complete LS. The operation time, intraoperative blood loss, and the length of stay in LS group and OS group were 100-200 min (mean: 150 ± 30 min) vs. 120-210 min (mean: 100 ± 30 min), 50-1,000 ml (mean: 150 ± 110 ml) vs. 60-900 ml (mean: 140 ± 50 ml) and 4-9 days (mean: 6.1 ± 2.2 days) vs. 8-14 days (mean: 11.3 ± 2.3 days), respectively. No deaths occurred in the two groups, and there are no significant differences between the two groups in terms of estimated blood loss, complications, length of stay, and operating time.
LS for treatment of massive splenomegaly is a feasible, effective, and safe surgical technique. Hypersplenism secondary to portal hypertension and liver cirrhosis are not supposed to be considered absolute contraindications to LS.
本研究旨在评估腹腔镜脾切除术(LS)治疗门静脉高压症和肝硬化继发脾功能亢进患者巨脾的可行性。
对2006年1月至2010年12月期间接受脾切除术的成年患者进行回顾性研究。我们对80例因门静脉高压症和肝硬化继发脾肿大或脾功能亢进的患者进行了脾切除手术,其中40例患者接受了LS,另外40例患者接受了开放手术(OS)。
在接受LS的患者中,2例转为OS,其他38例患者接受了完整的LS。LS组和OS组的手术时间、术中出血量和住院时间分别为100 - 200分钟(平均:150±30分钟)与120 - 210分钟(平均:100±30分钟)、50 - 1000毫升(平均:150±110毫升)与60 - 900毫升(平均:140±50毫升)以及4 - 9天(平均:6.1±2.2天)与8 - 14天(平均:11.3±2.3天)。两组均无死亡病例,两组在估计失血量、并发症、住院时间和手术时间方面无显著差异。
LS治疗巨脾是一种可行、有效且安全的手术技术。门静脉高压症和肝硬化继发脾功能亢进不应被视为LS的绝对禁忌证。